Search Result

Results for "

neuropsychiatric diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Acetyl-CoA synthetase (1) Adrenergic Receptor (1) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) Cholinesterase (ChE) (1) Dopamine Receptor (3) Drug Derivative (1) Drug Isomer (1) GABA Receptor (1) GPR52 (1) HDAC (1) Histamine Receptor (1) iGluR (1) mAChR (1) mGluR (1) Monoamine Transporter (1) Phosphodiesterase (PDE) (1) Phospholipase (1) REV-ERB (1) Trace Amine-associated Receptor (TAAR) (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (18)

By Targets:

5-HT Receptor (2)

Acetyl-CoA synthetase (1)

Adrenergic Receptor (1)

Biochemical Assay Reagents (1)

Carbonic Anhydrase (1)

Cholinesterase (ChE) (1)

Dopamine Receptor (3)

Drug Derivative (1)

Drug Isomer (1)

GABA Receptor (1)

GPR52 (1)

HDAC (1)

Histamine Receptor (1)

iGluR (1)

mAChR (1)

mGluR (1)

Monoamine Transporter (1)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

REV-ERB (1)

Trace Amine-associated Receptor (TAAR) (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (3)

Neurological Disease (18)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125751

UCSF924	Dopamine Receptor	Neurological Disease
UCSF924 is a potent and specific dopamine D4 receptor (DRD4) partial agonist with a EC₅₀ of 4.2 nM. UCSF924 has no off-target effects on more than 320 non-olfactory GPCRs. UCSF924 can be used for research in the field of neuropsychiatric diseases .

HY-117516

SR10067	REV-ERB	Neurological Disease Metabolic Disease
SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC₅₀ values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .

HY-148104

ACSS2-IN-2 1 Publications Verification	Acetyl-CoA synthetase	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .

HY-154980

GPR52 receptor modulator 1	GPR52	Neurological Disease
GPR52 receptor modulator 1 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases .

HY-128856

P7C3-OMe	Drug Derivative	Neurological Disease
P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer .

HY-W909149

TAAR1 agonist 3	Trace Amine-associated Receptor (TAAR) Adrenergic Receptor	Neurological Disease
TAAR1 agonist 3 is a trace amine-associated receptor 1 (TAAR1) agonist (pEC₅₀=7.6). TAAR1 agonist 3 is also a full agonist of the α_2A receptor (pEC₅₀=6). TAAR1 agonist 3 can be used in the study of neuropsychiatric diseases .

HY-W909173

TAAR1 agonist 2	Trace Amine-associated Receptor (TAAR) Histamine Receptor mAChR	Neurological Disease
TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC₅₀=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC₅₀=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases .

HY-120662

GSK1331268	mGluR	Neurological Disease
GSK1331268 is a selective, orally active agonist for mGluR2 with a pEC₅₀ of 6.9. GSK1331268 exhibits good blood-brain barrier penetration. GSK1331268 regulates glutamate signaling, and can be used in research of neurodegenerative and neuropsychiatric diseases .

HY-103522

AA29504	GABA Receptor	Neurological Disease
AA29504 is a ethyl carbamate with γ-aminobutyric acid (GABA_A(HY-L120) receptor activity. AA29504 inhibits the delivery of the neurotransmitter gamma-aminobutyric acid in the central nervous system. AA29504 can be used to research anxiety, insomnia and other neuropsychiatric diseases .

HY-E70395

Prolyl endopeptidase PE; PEP	Biochemical Assay Reagents	Neurological Disease
Prolyl Endopeptidase, highly active in brain and other tissues, catabolizes proline-containing peptides such as substance P, neurotensin, luteinizing hormone-releasing hormone, thyrotropin releasing hormone, bradykinin and angiotensin II. Prolyl Endopeptidase can be used for study of neuropsychiatric diseases such as stress disorder, depression, and schizophrenia .

HY-169951

Lu AF90103	iGluR	Neurological Disease
Lu AF90103 (Compound 42e) is a methyl ester prodrug of compound 42d capable of penetrating the blood-brain barrier. Compound 42d acts as a partial agonist of the GluN1/GluN2B complex, exhibiting 24% efficacy, and has an EC₅₀ value of 78 nM. Lu AF90103 plays an important role in neuropsychiatric diseases research .

HY-15977

(S)-P7C3-OMe	Drug Isomer	Neurological Disease
(S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease .

HY-19348

Pimelic Diphenylamide 106 4 Publications Verification RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII	HDAC Monoamine Transporter	Neurological Disease Cancer
Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC₅₀ values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .

HY-169163

BChE-IN-36	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with K_A values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC₅₀ values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .

HY-123446

JNJ-42259152	Phosphodiesterase (PDE)	Neurological Disease
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-109112R

Brilaroxazine (Standard)	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂ .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

neuropsychiatric diseases

Inhibitors & Agonists